Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med, 346, 92, 10.1056/NEJMoa011954 Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938 Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314 Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X Maemondo, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530 Sequist, 2013, Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J Clin Oncol, 31, 3327, 10.1200/JCO.2012.44.2806 Ng, 2012, A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer, Nat Med, 18, 521, 10.1038/nm.2713 Costa, 2014, The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial, Clin Cancer Res, 20, 2001, 10.1158/1078-0432.CCR-13-2233 Sos, 2009, PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR, Cancer Res, 69, 3256, 10.1158/0008-5472.CAN-08-4055 Vivanco, 2010, The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation, Proc Natl Acad Sci USA, 107, 6459, 10.1073/pnas.0911188107 Sharma, 2010, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations, Cell, 141, 69, 10.1016/j.cell.2010.02.027 Bivona, 2011, FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR, Nature, 471, 523, 10.1038/nature09870 Turke, 2010, Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC, Cancer Cell, 17, 77, 10.1016/j.ccr.2009.11.022 Yano, 2008, Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations, Cancer Res, 68, 9479, 10.1158/0008-5472.CAN-08-1643 Lee, 2013, Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study, Ann Oncol, 24, 2080, 10.1093/annonc/mdt127 Arasada, 2014, EGFR blockade enriches for lung cancer stem-like cells through notch3-dependent signaling, Cancer Res, 74, 5572, 10.1158/0008-5472.CAN-13-3724 Gao, 2007, Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas, J Clin Invest, 117, 3846, 10.1172/JCI31871 Fan, 2011, MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents, Cancer Res, 71, 4494, 10.1158/0008-5472.CAN-10-2668 Yang, 2013, Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three trials of afatinib in EGFR mutation-positive lung cancer, J Thorac Oncol, 8, S141 Yasuda, 2012, EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications, Lancet Oncol, 13, e23, 10.1016/S1470-2045(11)70129-2 Yasuda, 2013, Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer, Sci Transl Med, 5, 216ra177, 10.1126/scitranslmed.3007205 Inukai, 2006, Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer, Cancer Res, 66, 7854, 10.1158/0008-5472.CAN-06-1951 Lee, 2014, Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations, Cancer, 120, 2090, 10.1002/cncr.28711 Oxnard, 2011, Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation, Clin Cancer Res, 17, 1616, 10.1158/1078-0432.CCR-10-2692 Jackman, 2010, Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer, J Clin Oncol, 28, 357, 10.1200/JCO.2009.24.7049 Gandara, 2014, Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications, Clin Lung Cancer, 15, 1, 10.1016/j.cllc.2013.10.001 Shukuya, 2011, Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure, Lung Cancer, 74, 457, 10.1016/j.lungcan.2011.04.007 Weickhardt, 2012, Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer, J Thorac Oncol, 7, 1807, 10.1097/JTO.0b013e3182745948 Sequist, 2011, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Sci Transl Med, 3, 75ra26, 10.1126/scitranslmed.3002003 Yu, 2013, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers, Clin Cancer Res, 19, 2240, 10.1158/1078-0432.CCR-12-2246 Kobayashi, 2005, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N Engl J Med, 352, 786, 10.1056/NEJMoa044238 Yun, 2008, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP, Proc Natl Acad Sci USA, 105, 2070, 10.1073/pnas.0709662105 Balak, 2006, Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors, Clin Cancer Res, 12, 6494, 10.1158/1078-0432.CCR-06-1570 Bean, 2008, Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma, Clin Cancer Res, 14, 7519, 10.1158/1078-0432.CCR-08-0151 Costa, 2007, BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations, PLoS Med, 4, 1669, 10.1371/journal.pmed.0040315 Kobayashi, 2013, Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors, J Thorac Oncol, 8, 45, 10.1097/JTO.0b013e3182781e35 Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478 Takezawa, 2012, HER2 amplification: a potential mechanism of acquired resistance to egfr inhibition in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation, Cancer Discov, 2, 922, 10.1158/2159-8290.CD-12-0108 Ohashi, 2012, PNAS Plus: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1, Proc Natl Acad Sci USA, 109, E2127, 10.1073/pnas.1203530109 Zhang, 2012, Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer, Nat Genet, 44, 852, 10.1038/ng.2330 Zakowski, 2006, EGFR mutations in small-cell lung cancers in patients who have never smoked, N Engl J Med, 355, 213, 10.1056/NEJMc053610 Alam, 2010, Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung, Clin Lung Cancer, 11, E1, 10.3816/CLC.2010.n.046 Suda, 2011, Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib, J Thorac Oncol, 6, 1152, 10.1097/JTO.0b013e318216ee52 Chong, 2013, The quest to overcome resistance to EGFR-targeted therapies in cancer, Nat Med, 19, 1389, 10.1038/nm.3388 Cortot, 2014, Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas, Eur Respir Rev, 23, 356, 10.1183/09059180.00004614 Lin, 2012, Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients, Chemother Res Pract, 2012, 817297 Wu, 2010, Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer, Int J Cancer, 126, 247, 10.1002/ijc.24657 Goldberg, 2013, Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors, Oncologist, 18, 1214, 10.1634/theoncologist.2013-0168 Chmielecki, 2011, Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling, Sci Transl Med, 3, 90ra59, 10.1126/scitranslmed.3002356 Chaft, 2011, Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design, Clin Cancer Res, 17, 6298, 10.1158/1078-0432.CCR-11-1468 Watanabe, 2011, Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis, BMC Cancer, 11, 1, 10.1186/1471-2407-11-1 Yoshimura, 2013, Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed, J Thorac Oncol, 8, 96, 10.1097/JTO.0b013e3182762bfb Halmos, 2013, Erlotinib beyond progression study: randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses, Proc Am Soc Clin Oncol, 31 Park, 2014, 1223O * ASPIRATION: first-line erlotinib (E) until and beyond RECIST progression (PD) in Asian patients with EGFR mutation-positive NSCLC, Ann Oncol, 25, iv426, 10.1093/annonc/mdu349.2 Soria, 2015, Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial, Lancet Oncol, 16, 990, 10.1016/S1470-2045(15)00121-7 Kwak, 2005, Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib, Proc Natl Acad Sci USA, 102, 7665, 10.1073/pnas.0502860102 Ou, 2012, Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence, Crit Rev Oncol Hematol, 83, 407, 10.1016/j.critrevonc.2011.11.010 Yap, 2010, Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors, J Clin Oncol, 28, 3965, 10.1200/JCO.2009.26.7278 Murakami, 2012, Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4), Cancer Chemother Pharmacol, 69, 891, 10.1007/s00280-011-1738-1 Miller, 2012, Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial, Lancet Oncol, 13, 528, 10.1016/S1470-2045(12)70087-6 Yang, 2015, Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials, Lancet Oncol, 16, 141, 10.1016/S1470-2045(14)71173-8 Ellis, 2014, Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial, Lancet Oncol, 15, 1379, 10.1016/S1470-2045(14)70472-3 Katakami, 2013, LUX-lung 4: a phase ii trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both, J Clin Oncol, 31, 3335, 10.1200/JCO.2012.45.0981 Janjigian, 2014, Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations, Cancer Discov, 4, 1036, 10.1158/2159-8290.CD-14-0326 Park, 2014, Safety and efficacy of dacomitinib in Korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial, J Thorac Oncol, 9, 1523, 10.1097/JTO.0000000000000275 Reckamp, 2014, A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib, Cancer, 120, 1145, 10.1002/cncr.28561 Yoshimura, 2006, EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib, Lung Cancer, 51, 363, 10.1016/j.lungcan.2005.10.006 Jänne, 2007, Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non-small-cell lung cancer, J Clin Oncol, 25, 3936, 10.1200/JCO.2007.11.1336 Wong, 2009, A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors, Clin Cancer Res, 15, 2552, 10.1158/1078-0432.CCR-08-1978 Sequist, 2010, Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer, J Clin Oncol, 28, 3076, 10.1200/JCO.2009.27.9414 Zhou, 2009, Novel mutant-selective EGFR kinase inhibitors against EGFR T790M, Nature, 462, 1070, 10.1038/nature08622 Cross, 2014, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer, Cancer Discov, 4, 1046, 10.1158/2159-8290.CD-14-0337 Yang, 2014, Updated safety and efficacy from a phase I study of AZD9291 in patients with EGFR-TKI-resistant non-small cell lung cancer (NSCLC), Ann Oncol, 25, iv149, 10.1093/annonc/mdu331.9 Walter, 2013, Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M mediated resistance in NSCLC, Cancer Discov, 3, 1404, 10.1158/2159-8290.CD-13-0314 Soria, 2014, Interim phase 2 results of study CO-1686-008: a phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer, Eur J Cancer, 50, 199, 10.1016/S0959-8049(14)70731-2 Lee, 2014, Discovery of HM61713 as an orally available and mutant EGFR selective inhibitor, Cancer Res, 74 Kim, 2014, Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs), Proc Am Soc Clin Oncol, 32, 8011, 10.1200/jco.2014.32.15_suppl.8011 Sakagami, 2014, ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations, Cancer Res, 74, 1728, 10.1158/1538-7445.AM2014-1728 Murakami, 2014, 9LBA Antitumor activity of ASP8273, an irreversible mutant selective EGFR-TKI, in NSCLC patients with tumors harboring EGFR activating mutations and T790M resistance mutation, Eur J Cancer, 50, 198, 10.1016/S0959-8049(14)70730-0 Yap, 2013, Development of therapeutic combinations targeting major cancer signaling pathways, J Clin Oncol, 31, 1592, 10.1200/JCO.2011.37.6418 Harrington, 2013, Adaptive designs for dual-agent phase I dose-escalation studies, Nat Rev Clin Oncol, 10, 277, 10.1038/nrclinonc.2013.35 Regales, 2009, Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer, J Clin Invest, 119, 3000 Hirsch Janjigian, 2011, Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib, Clin Cancer Res, 17, 2521, 10.1158/1078-0432.CCR-10-2662 Akbay, 2013, Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors, Cancer Discov, 3, 1355, 10.1158/2159-8290.CD-13-0310 Gerlinger, 2012, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, 366, 883, 10.1056/NEJMoa1113205 Chouaid, 2014, Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01), Lung Cancer, 86, 170, 10.1016/j.lungcan.2014.08.016 Murtaza, 2013, Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA, Nature, 497, 108, 10.1038/nature12065 Kuang, 2009, Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer, Clin Cancer Res, 15, 2630, 10.1158/1078-0432.CCR-08-2592 Taniguchi, 2011, Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas, Clin Cancer Res, 17, 7808, 10.1158/1078-0432.CCR-11-1712 Thress, 2014, EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of technologies to support the clinical development of AZD9291, J Clin Oncol, 32, 8092, 10.1200/jco.2014.32.15_suppl.8092 Thress, 2015, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nat Med, 21, 560, 10.1038/nm.3854 Punnoose, 2012, Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib, Clin Cancer Res, 18, 2391, 10.1158/1078-0432.CCR-11-3148 Maheswaran, 2008, Detection of mutations in EGFR in cwirculating lung-cancer cells, N Engl J Med, 359, 366, 10.1056/NEJMoa0800668